BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 827,800 shares, a decline of 10.2% from the November 30th total of 921,900 shares. Based on an average daily trading volume, of 1,000,000 shares, the short-interest ratio is presently 0.8 days.

BioLineRx Stock Performance

BioLineRx stock traded up $0.00 during mid-day trading on Tuesday, reaching $0.21. The company’s stock had a trading volume of 1,383,498 shares, compared to its average volume of 529,643. BioLineRx has a twelve month low of $0.19 and a twelve month high of $1.59. The business has a 50 day moving average price of $0.33 and a 200-day moving average price of $0.53. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. The firm has a market cap of $17.11 million, a price-to-earnings ratio of -0.97 and a beta of 1.39.

Analysts Set New Price Targets

Several research analysts have weighed in on BLRX shares. StockNews.com began coverage on shares of BioLineRx in a report on Thursday, December 26th. They set a “hold” rating for the company. HC Wainwright decreased their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, November 25th.

Institutional Investors Weigh In On BioLineRx

Hedge funds have recently added to or reduced their stakes in the stock. Atria Investments Inc increased its holdings in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares during the period. PVG Asset Management Corp bought a new position in BioLineRx in the 2nd quarter worth about $70,000. Finally, CVI Holdings LLC bought a new stake in shares of BioLineRx during the second quarter valued at approximately $462,000. 1.56% of the stock is currently owned by institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.